Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European ...

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

Novo Nordisk submits a higher 7.2 mg dose of Wegovy for EMA approval, backed by trials showing 21% weight loss in obesity and ...

Stocks that pay dividends tend to outperform ones that don't. Consensus price targets for Novo Nordisk suggest the stock can ...

Danish pharmaceutical company Novo Nordisk (NVO) on Tuesday said that it has submitted an application to the European ...

Investing.com -- Novo Nordisk (NYSE: NVO) stock rose 1% after the company announced it has submitted an application to the ...

The International Organization for Migration (IOM) has partnered with the Novo Nordisk Foundation, a Danish enterprise ...

Shares of Novo Nordisk (NYSE:NVO) rose 1% following news that the company has submitted an application to the European Medicines Agency (EMA) to approve a higher dose of its obesity treatment, Wegovy.

The demand for obesity drugs in India is surging as Eli Lilly and Novo Nordisk compete. A Pakistani startup sends prosthetics ...

Fundsmith Equity Fund fell 1.9% in the first six months of the year, two percentage points less than what is perhaps the most ...

The health sector is witnessing notable developments, including the rising demand for obesity drugs in India as Eli Lilly and ...

The lack of details about which countries are involved and which companies will be impacted as a result of the new trade deal ...